Mounjaro®
Starting from £179.99/mo
Start journey Learn moreTirzepatide is not a biologic. It is a small synthetic peptide molecule, manufactured through chemical synthesis rather than derived from living cells — the defining distinction that separates biologics from conventional medicines. That said, the classification question has real practical consequences for patients, particularly around how the medicine works, how it is stored, and what happens if a biosimilar ever reaches the UK market. Tirzepatide is the active ingredient in Mounjaro, the once-weekly injection licensed in the UK for weight management. Because it is a prescription-only medicine, whether it suits you is a question for a qualified prescriber rather than a product label.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Most people searching whether tirzepatide is a biologic are not trying to pass a pharmacology exam. They want to know whether it behaves like a biologic, and what that means for sourcing, storage, switching and cost. Those are legitimate questions, so let's start there.
Biologics are medicines derived from living organisms: proteins, antibodies, hormones grown in cell cultures. They are large, structurally complex molecules that cannot be precisely replicated, which is why the medicines that follow them to market are called biosimilars rather than generics. Insulin is a biologic. Adalimumab is a biologic. Tirzepatide is neither.
Tirzepatide is a 39-amino-acid synthetic peptide, assembled in a laboratory through chemical synthesis. It is big enough to mimic two gut hormones simultaneously (GIP and GLP-1) but small enough to be manufactured consistently and without the living-cell infrastructure biologics require. The NHS medicines page for tirzepatide describes it as a dual GIP and GLP-1 receptor agonist, activating both pathways involved in appetite regulation and blood-sugar control. If you are still working out whether tirzepatide is Mounjaro and how those two names relate, that question is worth clearing up before going further. That dual action is why it sits apart from semaglutide, which targets GLP-1 alone.
The classification matters because it determines how any future lower-cost versions of tirzepatide would be regulated. Generic equivalents follow a different, simpler pathway than biosimilars. That distinction is years away from affecting UK patients, but it is worth understanding if you are comparing long-term cost trajectories. For now, tirzepatide is available as a branded prescription medicine.
Even though tirzepatide is not a biologic, it shares one practical feature with most biologics: it cannot survive your digestive system intact. Stomach acid and gut enzymes would break the peptide chain apart before it reached your bloodstream, which is why it is delivered by subcutaneous injection rather than a tablet.
Storage reflects the same fragility. The pre-filled KwikPen must be kept refrigerated at 2–8°C; exposure to heat or freezing can degrade the molecule. If you want to check quickly whether a pen has been stored correctly, hold it up to the light before injecting, the solution should be clear and colourless. Any cloudiness or particles is a reason to contact your prescriber before use. For the precise room-temperature window and the full storage rules, the Mounjaro Summary of Product Characteristics on the eMC is the definitive reference rather than any summary.
Injection sites rotate between the abdomen, thigh and upper arm. The rotating-site rule exists partly because peptides can cause localised tissue reactions if injected repeatedly into the same spot. None of this is unique to tirzepatide being a synthetic peptide; it would apply to a biologic in the same delivery format. The practical experience for the patient is largely the same.
The laboratory analysis of tirzepatide's peptide structure goes further into the chemistry if that level of detail is useful to you.
One reason the biologic label sometimes comes up is in discussions about where these medicines come from and how easy they are to counterfeit. Biologics are notoriously difficult to copy because of their manufacturing complexity; synthetic peptides are somewhat easier to produce, which is part of why counterfeit tirzepatide pens appeared on the UK market relatively quickly after the medicine was licensed.
The MHRA has publicly warned about fake weight-loss injection pens being sold through social media and unverified online sellers. A seller offering tirzepatide without requiring a prescription, or at a price far below the current UK market range, is a serious red flag, not a bargain. Eli Lilly's authorised supply chain, accessed through a GPhC-registered pharmacy, is the only safe route. You can verify any UK online pharmacy takes about thirty seconds on the GPhC register.
At nume, medicines are sourced through the licensed UK supply chain. That is not a marketing claim; it is the baseline a GPhC-registered pharmacy must meet. The cost context for Mounjaro helps explain what a legitimate price includes and why significant undercutting should prompt questions rather than a quick checkout.
Tirzepatide's classification as a synthetic peptide rather than a biologic does not change how it works in your body or what the clinical evidence says about it. The SURMOUNT-1 trial reported average weight reductions of around 20–21% at the 15mg dose over 72 weeks, figures that informed NICE's recommendation of tirzepatide (TA1026) for eligible adults. Those results came from people using a correctly sourced, clinically supervised prescription medicine.
If you are weighing up whether tirzepatide is the right option for you, the classification question is a reasonable starting point, but the prescriber's assessment is what determines suitability. They look at your BMI, any weight-related conditions, your current medicines, and your medical history, none of which a classification label can answer. For a fuller picture of what the medicine involves, tirzepatide explained for UK patients covers the practical detail, and you can compare it against how Mounjaro and tirzepatide relate to each other if that question is also on your list.
If you would like to explore whether tirzepatide is clinically suitable for you, start your free consultation with our prescribers, a real clinician reviews every application the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.